Brooklyn ImmunoTherapeutics to Present at the SNN Virtual Investor Conference on August 18, 2021
August 13 2021 - 1:21PM
Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX)
(“Brooklyn”), a biopharmaceutical company focused on exploring the
role that cytokine and gene editing/cell therapy can have in
treating patients with cancer, blood disorders, and monogenic
diseases, today announced that Chief Executive Officer Howard J.
Federoff, M.D., Ph.D., will present a corporate overview at the SNN
Virtual Investor Conference being held August 17 – 19, 2021.
Dr. Federoff will deliver his corporate presentation on August
18 at 12:00pm ET.
Investors can also request a one-on-one meeting with Dr.
Federoff to be arranged throughout the conference.
Investors can register here: REGISTER
About Brooklyn ImmunoTherapeuticsBrooklyn is
focused on exploring the role that cytokine, gene editing, and cell
therapy can have in treating patients with cancer, blood disorders,
and monogenic diseases.
Brooklyn’s most advanced program is IRX-2, a human cell-derived
cytokine therapy, studying the safety and efficacy of IRX-2 in
patients with head and neck cancer in Phase 2B. In a Phase 2A
clinical trial in head and neck cancer, IRX-2 demonstrated an
overall survival benefit. Additional studies are either underway or
planned in other solid tumor cancer indications.
Brooklyn has multiple next-generation cell and gene-editing
therapies in preclinical development for various indications
including acute respiratory distress syndrome, solid tumor
indications, as well as in vivo gene-editing therapies for rare
genetic diseases. For more information about Brooklyn and its
clinical programs, please visit www.BrooklynITx.com.
Investor Relations Contact:CORE
IR516-222-2560investors@brooklynitx.com
Media Contact:Jules AbrahamCORE
IR917-885-7378julesa@coreir.com
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Apr 2024 to May 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Brooklyn ImmunoTherapeutics Inc (American Stock Exchange): 0 recent articles
More News Articles